Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06869694
Recruiting Observational

Energy CT in Imaging and Diagnosis of Gastric Cancer

NCT06869694 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Observational
Started
2024-09-01
Last updated
2025-03-11

Condition(s) studied

Gastric CancerCT

Investigational drug(s) / intervention(s)

computerized tomography

computerized tomography: mpMRI and Photon-counting Detector CT scan

Study summary

Accurate preoperative prediction of risk stratification, treatment response, and survival prognosis in gastric cancer is important for improving clinical treatment decisions, prolonging patient survival, and improving patient quality of life. The purpose of this study is to investigate the performance of the multi-parametric magnetic resonance imaging (mpMRI) and Dual-/Muti-energy CT and photon-counting Detector CT(PCD-CT) in the diagnosis and management of gastric cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Pathological biopsy confirmed gastric cancer; 2. Surgery: patients undergoing radical gastrectomy. Patients undergoing exploratory abdominal surgery or palliative tumor resection were still included in the study when peritoneal metastasis or adjacent organ invasion was identified intraoperatively and radical surgical resection was not possible. Exclusion Criteria: 1. Refusal or inability to sign informed consent; 2. CT or MRI images are poor or the focus is small and CT images are not clear; 3. Patients with other tumors complicated with patients with important organ dysfunction.

Primary outcome measure(s)

  • Diagnostic and Predictive performance of Dual-/ Muti- energy CT and MRI in the treatment response and survival prognosis of gastric cancer — 3years
    Accuracy for both imaging techniques in the prediction of treatment response of gastric cancer.

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Zhengzhou University Zhengzhou China Recruiting

More The First Affiliated Hospital of Zhengzhou University trials in China

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma Enrolling by invitation
PCOS (Polycystic Ovarian Syndrome) Patients Recruiting
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer Starting soon
Pro-urokinase for Extended-Window Posterior Circulation Stroke Starting soon
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC Recruiting

Other trials for the same condition

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore Recruiting
Study for AZD4360 in Participants With Advanced Solid Tumours Active, not recruiting
Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site Recruiting
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30) Recruiting
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06869694 on ClinicalTrials.gov ↗ ← All trials in China